Dr. Pamela Brown FRSC joins the Oxford Drug Design Scientific Advisory Board

Oxford Drug Design is pleased to announce the appointment of Dr. Pamela Brown FRSC to the company’s Scientific Advisory Board. Dr. Brown has over 30 years’ experience in anti-infective drug discovery. Pam has previously led medicinal chemistry teams in hit to lead and lead optimisation phases of drug discovery at GlaxoSmithKline and legacy companies. In […]

Prof. David Livermore joins the Oxford Drug Design Scientific Advisory Board

Oxford Drug Design is pleased to announce the addition of Prof. David Livermore to our Scientific Advisory Board. David Livermore gained his BSc in 1978 and his PhD in 1983. He worked at the London Hospital Medical College from 1980 until 1997 when he joined the Health Protection Agency (now Public Health England), becoming Director […]

James B. Kahn, M.D. FIDSA, joins the Oxford Drug Design Scientific Advisory Board

Oxford Drug Design is pleased to announce the appointment of James B. Kahn, M.D. FIDSA, to the company’s Scientific Advisory Board. Dr. Kahn has deep and extensive knowledge of antibacterial drug development. He is Board-certified in both I.M. and I.D. After 18 years in the solo private practice of I.D. Medicine, James was recruited by […]